Clinical trials: Vorinostat
Non-Small-Cell Lung Carcinoma
Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)
Gefitinib is an orally active epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and produces 8-20% of response rates in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01027676
- Testing
- Study treatment
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia.
- Conditions
- Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00217412
- Testing
- vorinostat, isotretinoin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Vorinostat in Treating Patients With Kidney Cancer
This phase II trial is studying how well vorinostat works in treating patients with advanced kidney cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00278395
- Testing
- Vorinostat
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma.
- Conditions
- Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma
- Trial name
- NCT01208454
- Testing
- Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 13 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00882206
- Testing
- cytarabine, decitabine, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myelodysplastic Syndrome
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat may kill more cancer cells.
- Trial name
- NCT00818649
- Testing
- bortezomib, vorinostat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
The purpose of this study is to test the safety of sorafenib and vorinostat when given together to see what effects (good and bad) it has on the patient and their acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Myelodysplastic Syndromes
- Trial name
- NCT00875745
- Testing
- Sorafenib-Vorinostat
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Breast Cancer, Colorectal Cancer
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
This is an investigational study to determine the response rate of relapsed/refractory breast, colorectal and non-small cell lung cancer to oral suberoylanilide hydroxamic acid (SAHA), to evaluate PET as an earlier indicator of…
- Conditions
- Breast Cancer, Colorectal Cancer, Non-small-cell Lung Carcinoma
- Trial name
- NCT00126451
- Testing
- MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA), Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Clinical Trial of SAHA in Patients With Breast Cancer
Purpose: evaluate the safety of Vorinostat. evaluate the effectiveness of Vorinostat in treating breast cancer evaluate how the study subject's body reacts to Vorinostat, how these reactions relate to the subject's genes, and…
- Trial name
- NCT00416130
- Testing
- Vorinostat
- Where
- 2 sites in Singapore
- Volunteers
- 49 people
- Sponsor
- National University Hospital, Singapore
Lymphoma
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
This will be a phase I study of carfilzomib in combination with vorinostat in patients with relapsed/refractory B-cell lymphomas.
- Trial name
- NCT01276717
- Testing
- Drug: Carfilzomib, Vorinostat
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with alvocidib in treating patients with advanced solid tumors.
- Trial name
- NCT00324480
- Testing
- alvocidib, vorinostat, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06145633
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
The purposes of this study are: To determine the maximum tolerated dose (MTD) of SAHA administered every 12 hours for 14 consecutive days followed by 7 days of rest during the first two cycles (i.e., first 6 weeks) in patients…
- Trial name
- NCT00109109
- Testing
- MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer…
- Trial name
- NCT00821951
- Testing
- Vorinostat, Radiotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
HIV-1 Infection
Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART.
- Trial name
- XTRA (NCT03212989)
- Testing
- Vorinostat, HXTC
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated…
- Trial name
- NCT00702572
- Testing
- Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Squamous Cell Lung Cancer, Vulvar Cancer
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and…
- Conditions
- Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer
- Trial name
- PEVOsq (NCT04357873)
- Testing
- pembrolizumab; vorinostat
- Where
- 14 sites in France
- Volunteers
- 112 people
- Sponsor
- UNICANCER
Neuroblastoma
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people…
- Trial name
- N2011-01 (NCT02035137)
- Testing
- 131I-MIBG, Vincristine, Irinotecan
- Where
- 14 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Acute Myeloid Leukemia
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
This research is being done because treatment options are very limited and usually unsuccessful for Acute Myeloid Leukemia (AML) in older individuals, or younger people with disease that has relapsed and/or proven resistant to…
- Trial name
- NCT01534260
- Testing
- sorafenib, vorinostat and bortezomib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Hamid Sayar
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma
- Trial name
- NCT00121225
- Testing
- vorinostat
- Where
- 5 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)